Premenstrual Dysphoria: An Illustrative Example of How Serotonin Modulates Sex-Steroid—Related Behavior

CNS Spectrums

Volumn 6, Issue 2, 2001, Pages 141-149

  Eriksson, Elias ^a   Andersch, Björn ^a   ho, Hoi Por ^a   Landén, Mikael ^a   Sundblad, Charlotta ^a   Yonkers, Kimberly ^b   Steiner, Meir ^c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; CONTRACEPTIVE AGENT; ESTRADIOL; FLUOXETINE; PAROXETINE; PROGESTERONE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SEX HORMONE;

AFFECTIVE NEUROSIS; ANGER; ANORGASMIA; ANTICHOLINERGIC EFFECT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG SPECIFICITY; EMOTIONAL STRESS; FEMALE; HORMONAL REGULATION; HUMAN; IRRITABILITY; MOOD; PREMENSTRUAL DYSPHORIA; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEROTONIN RELEASE; SEXUAL DYSFUNCTION;

EID: 0034969797     PISSN: 10928529     EISSN: 21656509     Source Type: Journal    
DOI: 10.1017/S1092852900007902     Document Type: Article

References (61)

1. Eriksson, E, Sundblad, C, Yonkers, KA, et al. Premenstrual dysphoria and related conditions: symptoms, pathophysiology and treatment. In: Steiner, M, Yonkers, KA, Eriksson, E, eds. Mood Disorders in Women. London, UK: Martin Dunitz; 2000: 268–293.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Press; 1994: 715–718.
3. Rubinow, DR, Roy-Byrne, P, Hoban, MC, et al. Premenstrual mood changes: characteristic patterns in women with and without premenstrual syndrome. J Affect Disord. 1986; 10: 85–90.
4. Steiner, M, Streiner, DL, Steinberg, S, et al. The measurement of premenstrual mood symptoms. J Affect Disord. 1999; 53: 269–273.
5. Eriksson, E, Humble, M. Serotonin in psychiatric pathophysiology: a review of data from experimental and clinical research. In: Pohl, R, Gershon, S, eds. The Biological Basis of Psychiatric Treatment. Basel, Switzerland: Karger; 1990: 66–119.
6. Rosen, RC, Lane, RM, Menza, M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol. 1999; 19: 67–85.
7. Muse, KN, Cetel, NS, Futterman, LA, et al. The premenstrual syndrome: effects of “medical ovariectomy.” N Engl J Med. 1984; 311: 1345–1349.
8. Bäckström, T, Hammarbäck, S. Premenstrual syndrome—psychiatric or gynaecological disorder? Ann Med. 1991; 23: 625–633.
9. Schmidt, PJ, Nieman, LK, Danaceau, MA, et al. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998; 338: 209–216.
10. Leather, AT, Studd, JW, Watson, NR, et al. The treatment of severe premenstrual syndrome with goserelin with and without ‘add-back’ estrogen therapy: a placebo-controlled study. Gynecol Endocrinol. 1999; 13: 48–55.
11. Schmidt, PJ, Nieman, LK, Grover, GN, et al. Lack of effect of induced menses on symptoms in women with premenstrual syndrome. N Engl J Med. 1991; 324: 1174–1179.
12. Rowe, T, Sasse, V. Androgens and premenstrual symptoms—the response to therapy. In: Deneerstein, L, Frazer, I, eds. Hormones and Behaviour. Amsterdam, The Netherlands: Elsevier; 1986: 160–165.
13. Burnet, RB, Radden, HS, Easterbrook, EG, et al. Premenstrual syndrome and spironolactone. Aust N Z J Obstet Gynaecol. 1991; 31: 366–368.
14. Eriksson, E, Sundblad, C, Lisjö, P, et al. Serum levels of androgens are higher in women with premenstrual irritability and dysphoria than in controls. Psychoneuroen-docrinology. 1992; 17: 195–204.
15. Steiner, M, Coote, M, Wilkins, A, et al. Biological correlates of irritability in women with premenstrual dysphoria [abstract]. Eur Neuropsychopharmacol. 1997; 7(suppl 2);S172.
16. Bäckstrom, T, Aakvaag, A. Plasma prolactin and testosterone during the luteal phase in women with premenstrual tension syndrome. Psychoneuroendocrinology. 1981; 6: 245–251.
17. Bloch, M, Schmidt, PJ, Su, TP, et al. Pituitary-adrenal hormones and testosterone across the menstrual cycle in women with premenstrual syndrome and controls. Biol Psychiatry. 1998; 43: 897–903.
18. Ho, HP, Olsson, M, Westberg, L, et al. The serotonin reuptake inhibitor fluoxetine reduces sex steroid-related aggression in female rats: an animal model of premenstrual irritability. Neuropsychopharmacology. In press.
19. Woods, NF, Most, A, Dery, GK. Prevalence of perimen-strual symptoms. Am J Public Health. 1982; 72: 1257–64.
20. Su, TP, Schmidt, PJ, Danaceau, M, et al. Effect of menstrual cycle phase on neuroendocrine and behavioral responses to the serotonin agonist m-chlorophenylpiperazine in women with premenstrual syndrome and controls. J Clin Endocrinol Metab. 1997; 82: 1220–1228.
21. FitzGerald, M, Malone, KM, Li, S, et al. Blunted serotonin response to fenfluramine challenge in premenstrual dysphoric disorder. Am J Psychiatry. 1997; 154: 556–558.
22. Steiner, M, Yatham, LN, Coote, M, et al. Serotonergic dysfunction in women with pure premenstrual dysphoric disorder: is the fenfluramine challenge test still relevant? Psychiatry Res. 1999; 87: 107–115.
23. Rapkin, AJ. The role of serotonin in premenstrual syndrome. Clin Obstet Gynecol. 1992; 35: 629–636.
24. Hallman, J, Oreland, L, Edman, G, et al. Thrombocyte monoamine oxidase activity and personality traits in women with severe premenstrual syndrome. Acta Psychiatr Scand. 1987; 76: 225–234.
25. Eriksson, E, Ailing, C, Andersch, B, et al. Cerebrospinal fluid levels of monoamine metabolites. Neuropsychopharmacology. 1994; 11: 201–213.
26. Menkes, DB, Coates, DC, Fawcett, JP. Acute tryptophan depletion aggravates premenstrual syndrome. J Affect Disord. 1994; 32: 37–44.
27. Eriksson, E, Lisjö, P, Sundblad, C, et al. Effect of clomipramine in the premenstrual syndrome. Acta Psychiatr Scand. 1990; 81: 87–88.
28. Rickels, K, Freedman, EW, Sonderheimer, S, et al. Fluoxetine in the treatment of premenstrual syndrome. Curr Ther Res. 1990; 48: 161–166.
29. Stone, AB, Pearlstein, TB, Brown, WA. Fluoxetine in the treatment of late luteal phase dysphoric disorder. J Clin Psychiatry. 1991; 52: 290–293.
30. Sundblad, C, Hedberg, MA, Eriksson, E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology. 1993; 9: 133–145.
31. Sundblad, C, Modigh, K, Andersch, B, et al. Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr Scand. 1992; 85: 39–47.
32. Wood, SH, Mortola, JF, Chan, YF, et al. Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study. Obstet Gynecol. 1992; 80: 339–344.
33. Menkes, DB, Taghavi, E, Mason, PA, et al. Fluoxetine treatment of severe premenstrual syndrome. Br Med J. 1992; 305: 346–347.
34. Steiner, M, Steinberg, S, Stewart, D, et al. Fluoxetine in the treatment of premenstrual dysphoria. N Engl J Med. 1995; 332: 1529–1534.
35. Pearlstein, TB, Stone, AB, Lund, SA. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol. 1997; 17: 261–266.
36. Su, TP, Schmidt, PJ, Danaceau, MA, et al. Fluoxetine in the treatment of premenstrual dysphoria. Neuropsychopharmacology. 1997; 16: 346–356.
37. Ozeren, S, Corakci, A, Yucesoy, I, et al. Fluoxetine in the treatment of premenstrual syndrome. Eur J Obstet Gynecol Reprod Biol. 1997; 73: 167–70.
38. Yonkers, KA, Halbreich, U, Freeman, E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment: a randomized controlled trial. JAMA. 1997; 278: 983–988.
39. Young, SA, Hurt, PH, Benedek, DM, et al. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. J Clin Psychiatry. 1998; 59: 76–80.
40. Freeman, EW, Rickels, K, Arredondo, F, et al. Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. J Clin Psychopharmacol. 1999; 19: 3–8.
41. Freeman, EW, Rickels, K, Sondheimer, SJ, et al. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch Gen Psychiatry. 1999; 56: 932–939.
42. Jermain, DM, Preece, CK, Sykes, RL, et al. Luteal phase sertraline treatment for premenstrual dysphoric disorder: results of a double-blind, placebo-controlled, crossover study. Arch Earn Med. 1999; 8: 328–332.
43. Eriksson, E, Hedberg, MA, Andersch, B, et al. The SRI paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology. 1995; 12: 167–176.
44. Wikander, I, Sundblad, C, Andersch, B, et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol. 1998; 18: 390–398.
45. Halbreich, U, Smoller, JW. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry. 1997; 58: 399–402.
46. Steiner, M, Korzekwa, M, Lamont, J, et al. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol Bull. 1997; 33: 771–774.
47. Taghavi, E, Menkes, DB, Howard, RC, et al. Premenstrual syndrome: a double-blind controlled trial of desipramine and methylscopolamine. Int Clin Psychopharmacol. 1995; 10: 119–122.
48. Brzezinski, AA, Wurtman, JJ, Wurtman, RJ, et al. d-Fen-fluramine suppresses the increased calorie and carbohydrate intakes and improves the mood of women with premenstrual depression. Obstet Gynecol. 1990; 76: 296–301.
49. Steinberg, S, Annable, L, Young, SN, et al. A placebo-controlled clinical trial of L-tryptophan in premenstrual dysphoria. Biol Psychiatry. 1999; 45: 313–320.
50. Rickels, K, Freeman, E, Sondheimer, S. Buspirone in treatment of premenstrual syndrome. Lancet. 1989; 1: 777.
51. Kavoussi, R, Armstead, P, Coccaro, E. The neurobiology of impulsive aggression. Psychiatr Clin North Am. 1997; 20: 395–403.
52. Yonkers, KA. The association between premenstrual dysphoric disorder and other mood disorders. J Clin Psychiatry. 1997; 58(suppl 15):19–25.
53. Yonkers, KA. Anxiety symptoms and anxiety disorders: how are they related to premenstrual disorders? J Clin Psychiatry. 1997; 58(suppl 3):62–67.
54. Freeman, EW. Premenstrual syndrome: current perspectives on treatment and etiology. Curr Opin Obstet Gynecol. 1997; 9: 147–153.
55. Collins, A, Cerin, A, Coleman, G, et al. Essential fatty acids in the treatment of premenstrual syndrome. Obstet Gynecol. 1993; 81: 93–98.
56. Wyatt, KM, Dimmock, PW, Jones, PW, et al. Efficacy of vitamin B6 in the treatment of premenstrual syndrome: systematic review. Br Med J. 1999; 318: 1375–1381.
57. Thys-Jacobs, S, Starkey, P, Bernstein, D, et al. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms: Premenstrual Syndrome Study Group. Am J Obstet Gynecol. 1998; 179: 444–452.
58. Mortola, JF, Girton, L, Fischer, U. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. J Clin Endocrinol Metab. 1991; 72: 252A–252F.
59. Mezrow, G, Shoupe, D, Spicer, D, et al. Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome. Fertil Steril. 1994; 62: 932–937.
60. Watson, NR, Studd, JW, Savvas, M, et al. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet. 1989; 2: 730–732.
61. O'Brien, PMS, Abukhalil, IEH, Henshaw, C. Premenstrual syndrome. Curr Opin Obstet Gynaecol. 1995; 5: 30–35.